Emanuela Marcucci
City of Hope National Medical Center
5 Papers
8 Citations
Emanuela Marcucci is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: T cell & Antigen. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial
Lihua E. Budde,Joo Y. Song,Young L. Kim,Suzette Blanchard,Jamie Wagner,Anthony S. Stein,Lihong Weng,Marissa Del Real,Rochelle Hernandez,Emanuela Marcucci,Jennifer K Shepphird,Xiuli Wang,Brent L. Wood,Guido Marcucci,Christine E. Brown,Stephen J. Forman +15 more
TL;DR: The primary objective is to test the safety and activity of escalating doses of CD123CAR T cells for patients with relapsed or refractory AML and BPDCN, and all toxicities were reversible and manageable.
152
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
TL;DR: Mosunetuzumab, an anti-CD20/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R/R) follicular lymphoma as mentioned in this paper .
Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia
Tongyuan Xue,Marissa Del Real,Emanuela Marcucci,Candida Toribio,Sonia Maryam Setayesh,Stephen J. Forman,David Horne,Lihua E. Budde +7 more
TL;DR: CD33CAR T cells significantly decreased leukemic burden and prolonged overall survival compared to mock T cells in vivo, and checkpoint blockade targeting programmed death-1/programmed death-ligand 1 (PD-L1) has shown survival benefits, particularly in combination with HMA, for patients with r/r AML.
8
Anti-IL1RAP/CD3 Bispecific Antibody (BsAb) Is a Promising Novel and Effective Therapy for Acute Myeloid Leukemia (AML)
Weixu Meng,Marissa Del Real,Guowei Wei,Rochelle Hernandez,Emanuela Marcucci,Allen Lin,Tinisha McDonald,Dandan Zhao,Herman Wu,Nadia Carlesso,Larry W. Kwak,Ling Li,Ya-Huei Kuo,Anthony S. Stein,Vinod Pullarkat,Ryotaro Nakamura,Steven T. Rosen,Stephen J. Forman,Bin Zhang,Lihua E. Budde,Guido Marcucci +20 more
TL;DR: It is hypothesized that an anti-IL1RAP/CD3 BsAb could preferentially target LSCs and LPCs while sparing normal HSCs, thereby offering a window of therapeutic opportunity for AML patients.
3
Targeting miR-126 in Ph+ acute lymphoblastic leukemia
Junjing Qiao,Da-wei Zhao,Le Xuan Truong Nguyen,Fang Chen,Chen Liang,L Ghoda,Nora Heisterkamp,Emanuela Marcucci,Ya-Huei Kuo,Guido Marcucci,Bin Amber Zhang +10 more
TL;DR: To fully elucidate the leukemogenic role of miR-126 in BCR::ABL1 ALL, a series of genetically engineered mouse models (GEMMs) of p190-BCR::ABl1 ALL with either global or compartmentalized (hematopoietic or endothelial) miR -126 overexpression (OE) or knockout (KO) were produced.
1